Sarah Rutherford, MD.
For patients with diffuse large B-cell lymphoma (DLBCL) who have more aggressive disease and are less likely to respond to chemotherapy, it is possible that they may have 2 of the rarer DLBCL subtypes that require different treatments, according to Sarah Rutherford, MD.
on Hematologic Malignancies.
OncLive: Please provide an overview of your presentation on DLBCL.
I focused on the most aggressive cases of DLBCL, which are called double-hit lymphomas. Then, there is another category called double-protein expressor lymphomas. My focus and research is with these more difficult-to-treat diseases and coming up with novel strategies to try to improve the cure rates.
First, I went over the diagnoses and the current treatment strategies. I talked about some of the clinical trials that we have opened and some other exciting treatments that we have planned for the future.
Can you discuss the features of each of these subtypes and highlight the prevalence of them?
As a background, DLBCL is the most common type of non-Hodgkin lymphoma and also the most common type, overall, of lymphoma. It is an aggressive disease that is usually cured in about two-thirds of patients using R-CHOP. For that other one-third of patients who are not cured, there have been strategies over the last 10 years or so to try and figure out what is different about those patients and what can we do to get them cured, as well.
... to read the full story